NEW HAVEN, Conn., Oct. 28, 2022 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. BTIBIOAF(the “Company” or “Bioasis”), a multi-asset rare and rare disease biopharmaceutical company developing clinical-stage programs based on epidermal growth factors and a differentiated, proprietary xB3 ™ platform for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, announced today that it has released its unaudited quarterly financial statements and the Management discussion and analysis for the period ended August 31, 2022. All are available under the company’s profile on SEDAR at www.sedar.com and on the company’s website at www.bioasis.us.
On behalf of the Board of Directors of Bioasis Technologies Inc.
Deborah Rathjen, Ph.D., Chair of the Board
Consequences:
Facebook
Instagram
LinkedIn
Twitter
BTI FIN
About bioasis
Bioasis Technologies Inc. is a multi-asset orphan and rare disease biopharmaceutical company developing clinical-stage programs based on Epidermal Growth Factors and xB3 ™ platform, a proprietary technology for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The delivery of therapeutics across the blood-brain barrier represents the ultimate frontier in the treatment of neurological disorders. Bioasis’ internal development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. More information about the company can be found at www.bioasis.us.
Forward-Looking Statements
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities laws that may not be historical facts and other statements containing the words “believe,” “may” , “to plan”, …
